Leica Biosystems and Bristol-Myers Squibb Enter Into a Development and Commercialization
Collaboration for Companion Diagnostics that Support Targeted Therapies
NUSSLOCH, GERMANY, August 7, 2014. Leica Biosystems, today announced an agreement with Bristol- Myers Squibb Company (NYSE: BMY) to collaborate on developing companion diagnostics on the Leica BOND system for use as an aid in selecting patients for treatment with certain pharmaceuticals developed, or to be developed, by Bristol-Myers Squibb. Other terms of the agreement were not disclosed.“We are pleased to be working with Bristol-Myers Squibb, on diagnostics for cancer and other therapies on the Leica BOND platform,” added Matthias Weber, MD, President of Leica Biosystems. “This partnership is an example of Leica’s continued growth in Companion Diagnostics. In this field the capabilities to supply high quality In Vitro Diagnostic products are critical requirements. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests”.
Source: Leica Biosystems
